Abstract
Background Previous studies have reported the association between myocardial infarction (MI) and air pollution (AP). However, limited information is available regarding the long-term effects of AP on the relative incidence rates of ST-elevation MI (STEMI) and Non-ST-elevation MI (NSTEMI).
Methods Study subjects were enrolled from the Korea Acute MI registry (KAMIR) and KAMIR-National Institutes of Health (NIH). A total of 45,619 eligible patients with AMI were enrolled between January 2006 and December 2015. We investigated the association between long-term exposure to AP and compared the incidence of STEMI with those of NSTEMI. Mixed-effect regression models were used to examine the association between the annual average ambient AP before MI onset and the incidence of STEMI compared with that of NSTEMI, and to evaluate the association of AP with the incidence of in-hospital cardiogenic shock.
Results After mixed-effect regression model analysis, each 1 μg/m3 increase in particulate matter (PM) 10 µm or less in diameter (PM10) was associated with increased incidence of STEMI compared with NSTEMI (odds ratio [OR]:1.009, 95% Confidence Interval [CI]: 1.002–1.016; p = 0.012). For in-hospital cardiogenic shock complication, each 1 μg/m3 increase in PM10 and 1 part per billion increase in SO2 were associated with increased risk, PM10 (OR:1.033, 95% CI, 1.018–1.050; p < 0.001), SO2 (OR:1.104, 95% CI, 1.006–1.212; p = 0.037), respectively.
Conclusion A high concentration of air pollutants, particularly PM10, was an environmental risk factor for an increase incidence of development of STEMI. PM10 and SO2 were found to be risk factors for in-hospital cardiogenic shock complications. Policy-level strategies and clinical efforts to reduce AP exposure are necessary to prevent the incidence of STEMI and severe cardiovascular complications.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
This research was supported by grants (2020ER630800 and 2022ER090900) from the Korea Centers for Disease Control and Prevention. (https://www.kdca.go.kr/). The funding organization had no role in the design and administration of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, or approval of the manuscript; nor the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board (IRB) of Korea University Guro Hospital (KUGH, #2016GR0740) and was conducted in accordance with the principles of the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data cannot be shared publicly because of the KAMIR group policy. Data are available from the Chonnam National University Hospital Institutional Data Access / Ethics Committee (contact via research manager) for researchers who meet the criteria for access to confidential data. Contact information: Research manager: Kyung Hoon Cho, E-mail: zarazoro{at}hanmail.net, Telephone: +82 62-220-5272